Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider

U.S. Intravenous Immunoglobulin Market to Reach USD 16.58 Billion and Europe USD 8.64 Billion by 2035 as Neurological Indication Expansion and Plasma Fractionation Capacity Drive Growth.

Austin, United States, Sept. 09, 2026 (GLOBE NEWSWIRE) — According to SNS Insider, The Intravenous Immunoglobulin Market size was valued at USD 14.98 Billion in 2025 and is expected to reach USD 30.83 Billion by 2035, growing at a CAGR of 7.49% from 2026 to 2035. Demand is rising due to a growing number of immunodeficiency, autoimmune, and neurological disorders requiring immunoglobulin-based treatment, supported by growing disease awareness, improving diagnosis, and increased use of immunoglobulins in hospitals and specialty centers. Since IVIG is derived from human plasma, supply dynamics remain closely tied to plasma collection and processing capacity, and industry players continue investing in manufacturing plants and plasma collection to keep pace with rising demand.

Expanding plasma collection and fractionation capacity, growing clinical use of IVIG beyond primary immunodeficiency, and development of subcutaneous immunoglobulin alternatives are playing an important role in intravenous immunoglobulin market modernization, as specialty clinics focused on neurology and immunology streamline infusion protocols and patient monitoring.

Download the Intravenous Immunoglobulin Market Sample Report: https://www.snsinsider.com/sample-request/7356

Intravenous Immunoglobulin Market Key Highlights

• Market size, 2025: USD 14.98 Billion
• Market forecast, 2035: USD 30.83 Billion
• CAGR: 7.49% from 2026 to 2035
• Largest region: North America
• Fastest-growing region: Asia Pacific
• Largest product type: IgG, approximately 74.75% share in 2025
• Fastest-growing product type: Recombinant Immunoglobulins
• Largest application: Immunodeficiency Diseases
• Fastest-growing application: Neurological Disorders
• Largest distribution channel: Hospital Pharmacies, approximately 57.10% share in 2025
• Fastest-growing distribution channel: Specialty Pharmacy
• Largest end-user: Hospitals
• Fastest-growing end-user: Specialty Clinics, approximately 8.61% CAGR

Market Relevance

Intravenous immunoglobulin therapy has become an integral part of contemporary immunology and neurology care, serving as first-line treatment for numerous immune disorders while its clinical use continues to expand into neurological conditions including chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, and Guillain-Barre syndrome. Growing disease awareness and improving diagnosis rates continue to widen the population of patients relying on immunoglobulin-based therapy.

Intravenous Immunoglobulin Market Overview

The market comprises IgG and recombinant immunoglobulin products distributed through hospital and specialty pharmacies, used across hospitals and specialty clinics for immunodeficiency and neurological disease treatment. IgG products remain central to both replacement and immunomodulatory therapy given their broad pharmacological versatility, while recombinant immunoglobulins are emerging as manufacturers seek to reduce dependence on donor plasma supply. Hospital pharmacies retain established infrastructure for administering plasma-derived therapies, while specialty pharmacies are increasingly enabling home-based treatment.

Strategic Market Outlook

Opportunities for growth lie in continued development of subcutaneous immunoglobulin alternatives, which can ease plasma supply pressure while preserving intravenous formulations for acute, high-dose requirements. Rising demand in emerging economies presents a further opportunity, as expanding reimbursement pools and improving healthcare access extend IVIG availability to previously underserved patient populations.

Plasma supply dependency and tariff-driven cost pressure remain major constraints. Because IVIG products are derived from human plasma, supply is directly tied to donor recruitment and fractionation capacity, and a 100% United States tariff on imported finished IVIG products effective since October 2025 has sharply raised landed costs for non-domestic brands, complicating supply chain and procurement planning.

Intravenous Immunoglobulin Market Regional Analysis

North America held the largest share of the global market in 2025, supported by well-established reimbursement pathways, high per-capita spending, and IVIG’s role as first-line treatment for several critical immune disorders. The United States accounted for approximately 84.90% of North American revenue, home to key plasma-derivative therapy producers and established healthcare reimbursement systems, while Canada contributes a smaller but growing share as immunotherapy adoption rises.

The U.S. Intravenous Immunoglobulin Market was valued at USD 7.71 Billion in 2025 and is expected to reach USD 16.58 Billion by 2035, growing at a CAGR of 7.95% from 2026 to 2035. A 100% import duty on the landed cost of IVIG therapy products, implemented in October 2025, has significantly increased costs of foreign IVIG products in the domestic market.

The Europe Intravenous Immunoglobulin Market held approximately 29% of the global market in 2025, valued at USD 4.34 Billion, and is expected to reach USD 8.64 Billion by 2035, growing at a CAGR of 7.10% from 2026 to 2035. Growth is supported by well-established national health insurance coverage and strong plasma collection infrastructure. Germany accounted for approximately 27.30% of European revenue in 2025, supported by its concentration of plasma fractionation facilities, while France, the U.K., and Italy contribute through continued investment in plasma collection capacity.

The Asia-Pacific region is the fastest-growing globally, supported by rapid healthcare access gains and policy reform. China accounted for approximately 36.50% of regional revenue in 2025, supported by expanding domestic plasma collection infrastructure, while Japan and South Korea contribute through advanced healthcare systems and plasma fractionation capability.

Buy the Intravenous Immunoglobulin Market Report with Competitive Analysis and 2035 Forecast: https://www.snsinsider.com/checkout/7356

Intravenous Immunoglobulin Market Segment Analysis

By Product Type: IgG accounted for around 74.75% market share in 2025, supported by its pharmacological suitability for both replacement and immunomodulatory therapy across the broadest range of immune disorders. Recombinant Immunoglobulins is the fastest-growing segment, as manufacturers develop next-generation products that reduce dependence on donor plasma supply.

By Application: Immunodeficiency Diseases held the largest share in 2025, supported by IVIG’s established use as first-line therapy. Neurological Disorders is the fastest-growing application, supported by expanding clinical use in chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, and Guillain-Barre syndrome.

By Distribution Channel: Hospital Pharmacies accounted for around 57.10% market share in 2025, supported by established infrastructure for administering plasma-derived therapies requiring clinical supervision. Specialty Pharmacy is the fastest-growing channel, as it increasingly facilitates at-home treatment outside traditional hospital settings.

By End-User: Hospitals held the largest share in 2025, anchored by comprehensive clinical infrastructure required for administering acute, high-dose IVIG treatment. Specialty Clinics are the fastest-growing segment, at around 8.61% CAGR, as clinics focused on neurology and immunology streamline infusion protocols and patient monitoring.

Intravenous Immunoglobulin Market Key Trends

• Continuous expansion of plasma collection and fractionation capacity supporting rising global treatment demand
• Rising clinical use of IVIG beyond primary immunodeficiency broadening the therapeutic opportunity landscape
• Expanding neurological indications, including chronic inflammatory demyelinating polyneuropathy, widening patient populations
• Specialty clinics focused on neurology and immunology streamlining infusion protocols and patient monitoring
• Manufacturers developing subcutaneous immunoglobulin alternatives while preserving intravenous formulations for acute needs

Major key players include

• CSL Behring
• Grifols S.A.
• Takeda Pharmaceutical Company Limited
• Kedrion Biopharma
• Octapharma AG
• Baxter International Inc.
• Biotest AG
• LFB Biotechnologies SAS
• Bio Products Laboratory Ltd.
• China Biologic Products Holdings Inc.
• Hualan Biological Engineering Inc.
• ADMA Biologics, Inc.
• Sanquin Plasma Products B.V.
• GC Biopharma Corp.
• Shanghai RAAS Blood Products Co., Ltd.
• Emergent BioSolutions Inc.
• KabaFusion
• Green Cross Corporation
• Bharat Serums and Vaccines Limited
• Prothya Biosolutions

Explore the Complete Intravenous Immunoglobulin Market Report: https://www.snsinsider.com/reports/intravenous-immunoglobulin-market-7356

CONTACT: About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315-961-9094 (US) Email: info@snsinsider.com 

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaEveningPost.com takes no editorial responsibility for the same.